Σellas Biopharma Neuro AG is a Research & Development company that gears towards the treatment of neurological diseases, such as Parkinson’s and other basal ganglia disorders.
Through the establishment of Σellas Biopharma Neuro AG Σellas Life Science Group is actively involved in the in-licensing and development of innovative and promising drugs in various neurological indications, putting these drugs through clinical development. Having acquired an excellent know-how and expertise in clinical trials (Phases I-IV) after years of research and collaboration with pharmaceutical, biotechnology companies and CROs, Σellas Life Sciences Group invests in Σellas Biopharma Neuro AG to become an active player as a service provider in drug development.
Σellas Biopharma Neuro AG is a CNS specialized biopharmaceutical research and development company with main focus on Parkinson’s & Parkinson-like Diseases. The clinical and regulatory development program entails conducting Phase II clinical studies under the FDA 505(b)(2) regulatory path and the European EMA in order to develop the rich treatment portfolio pipeline in Parkinson’s Disease, Progressive Supranuclear Palsy, Catatonia, Obsessive-compulsive Disorders, Stroke and more.